Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SNCG
REST API REST API
Homo sapiens
SNCG is differentially expressed in 179 experiments: 121 organism parts: amygdala, hypothalamus, ... (119 more);, 130 disease states: normal, glioblastoma, ... (128 more);, 44 cell types 248 cell lines 19 compound treatments and 62 other conditions.
Synonyms SR, BCSG1, persyn
Orthologs sncga (Danio rerio)   Q9I9H0_CHICK (Gallus gallus)   Sncg (Mus musculus)   sncgb (Danio rerio)   SYUG_BOVIN (Bos taurus)   Sncg (Rattus norvegicus)   sncg (Xenopus laevis)   SNCG (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytoskeleton, axon, cytoplasm, adult locomotory behavior, spindle, microtubule organizing center, axon terminus, perinuclear region of cytoplasm, regulation of neurotransmitter secretion, neuronal cell body, regulation of dopamine secretion
InterPro Term Synuclein, Synuclein_gamma
UniProt Accession O76070, Q6FHG5, F8W754
Search EB-eye ENSG00000173267
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (30 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
PC3
2
E-MEXP-2034, E-GEOD-5258
MDAMB175VII
2
E-MTAB-62, E-MTAB-37
MOLT4
2
E-MTAB-37, E-MTAB-62
SW480
2
E-GEOD-18005, E-MEXP-1014
HL-60
1
2
E-MTAB-37, E-GEOD-24147, E-GEOD-5258
242 more value(s).


Cell type

studied in E-AFMX-5, E-GEOD-18811, E-GEOD-22373, E-MTAB-24, E-MTAB-25, ... (23 experiments)

Factor Value U/D Experiments
monocyte
2
E-MEXP-583, E-GEOD-22373
effector memory T cell
1
E-GEOD-3982
leydig cell
1
E-MTAB-25
neutrophil
1
E-GEOD-12662
n/a
1
E-MTAB-24
erythropoietic
1
E-GEOD-9894
38 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-GEOD-1869, E-MEXP-2069, ... (40 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
lipoma
2
E-GEOD-6481, E-MTAB-62
glioblastoma
1
2
E-GEOD-4290, E-MTAB-62, E-MEXP-567
normospermic
1
E-GEOD-6872
thyroid carcinoma
1
E-MTAB-37
124 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-3284, E-GEOD-412, E-GEOD-2803, E-GEOD-5824, ... (12 experiments)

Factor Value U/D Experiments
granulocyte macrophage-colony stimulating factor
1
E-GEOD-2803
4-hydroxytamoxifen
1
1
E-MEXP-2241
ethanol
1
E-MEXP-2241
vanadium pentoxide
1
E-GEOD-5339
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
Cxcl12
1
E-GEOD-7307
13 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
86
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-20499, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-3140, E-MEXP-2283, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-21138, E-GEOD-3013

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-108

Genotype
studied in E-TABM-763, E-TABM-1029, E-GEOD-17476, E-MEXP-421, E-GEOD-2292, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-20540

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-GEOD-1926, E-GEOD-19330, ... (17 experiments)

Infection
studied in E-GEOD-12108, E-MEXP-561

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-TABM-84

Phenotype
studied in E-GEOD-1309, E-GEOD-21750, E-GEOD-1657

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10797

RNAi
studied in E-GEOD-1703, E-MEXP-1509, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-TABM-147

Vehicle
studied in E-GEOD-5258

Processing time: 0.537 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM